Eli Lilly and Company

Celltech R&d Limited

Manisha Naik

Daniel Christopher Brookings

Barry John Langham

Jeremy Martin Davis

Nicholas Paul Camp

Richard Jeremy Franklin

Rachel Jane Cubbon

The present invention provides compounds of the Formula below: where R is H or &#x2014;CH; methods of treating patients for hypertriglyceridemia and cardiovascular disease including dyslipidemia and atherosclerosis, and processes for preparing the compounds.

DGAT2 inhibitors

Compounds of formula (1) are described in which Rand Ris each independently a hydrogen atom or a group R, or Rand Rtogether form an oxo (&#x2550;O) or thio (&#x2550;S) group; X is a N atom or an optionally substituted CH group: Y is a &#x2014;O&#x2014; or &#x2014;S&#x2014; atom or &#x2014;SO&#x2014; or &#x2014;SO&#x2014; group or an optionally substituted &#x2014;CH&#x2014; or &#x2014;NH&#x2014; group with the proviso that when Rand Rtogether form an oxo (&#x2550;O) or thio (&#x2550;S) group Y is an optionally substituted &#x2014;CH&#x2014; or &#x2014;NH-group; Lis a covalent bond or a linker atom or group; p is zero or the integer 1; Alkis an optionally substituted Caliphatic or Cheteroaliphatic chain; n is zero the integer 1, 2 or 3 with the proviso that when n is zero Y is an optionally substituted &#x2014;CH&#x2014; group; Ar is an optionally substituted Caromatic or Cheteroaromatic group; m is zero or the integer 1, 2 or 3; q is zero or the integer 1 or 2; R, Rand Rare hydrogen atoms or the substituents described in the patent specification; and the salts, solvates, hydrates and N-oxides thereof. The compounds are potent and selective inhibitors of p38 kinase and are useful in the treatment of immune or inflammatory disorders.

Pyridine and pyrimidine derivatives

Growing community of inventors

Reading, United Kingdom

Manisha Naik